Strona główna・Stock List・Geron Corp

Geron Corp

Open

SectorHealthcare

1.43

Buy Sell

Overview

Share price change

24h

Current

Min

1.41

Max

1.45

Key metrics
By Trading Economics
Income	25M -3.6M
Sales	3.8M 52M
EPS	-0.005
Profit margin	-7.026
Employees	258
EBITDA	27M 3.8M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+175.86% upside

Dividends
By Acuity
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	-82M 924M
Previous open	1.43
Previous close	1.43

News Sentiment

By Acuity

50%

138 / 340 Ranking in Healthcare

Geron Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 lip 2026, 10:11 UTC

Shares of Geron Corp are higher in pre-market hours, trading above their 20-day moving average. No specific company news was identified.

22 lip 2026, 18:51 UTC

Geron Corp shares are lower today amid broader market trends, as crude oil prices surge due to geopolitical tensions.

21 lip 2026, 23:41 UTC

Geron Corp shares are lower in after-market trading, declining to their lowest point since Tuesday's close. No specific news was identified to explain the drop.

20 lip 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Peer Comparison

Price change

Geron Corp Forecast

Price Target

By TipRanks

175.86% upside

12 Months Forecast

Average 4 USD 175.86%

High 5 USD

Low 3 USD

Based on 4 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Geron Corp - Dist in the past 3 months.

Sentiment

By Acuity

138 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.